Probiotic Formulation and Method for Weight Loss Treatment

• US 20190307816A1
• Filed: 04/05/2018
• Published: 10/10/2019
• Est. Priority Date: 04/05/2018
• Status: Active Grant

• Current Assignee: Hooman M. Melamed
• Original Assignee: Hooman M. Melamed
• Inventors: Melamed, Hooman M.
• Granted Patent: US 10,780,135 B2
• Time in Patent Office: Days
• CPC Class Codes: A23L 33/135 Bacteria or derivatives thereof, e.g. probiotics
• CPC Class Codes: A23L 33/30 Dietetic or nutritional methods, e.g. for losing weight A23L33/10 takes precedence
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/733 Fructosans, e.g. inulin
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/0095 Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006
• CPC Class Codes: A61K 9/205 Polysaccharides, e.g. alginate, gums; Cyclodextrin
• CPC Class Codes: A61K 9/4866 Organic macromolecular compounds
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents

Abstract

A composition of probiotics is provided which promotes weight loss and maintenance thereof. More particularly, a probiotic mixture of lactobacillus gasseri, lactobacillus fermentum, and lactobacillus rhamnosus are provided to reduce body adiposity, decrease inflammation of adipose tissue, and enhance metabolism in optional combination with prebiotics and excipients such as flow agents and binders. A method of administering the probiotic composition to an individual user is also provided.

Claims

1. A probiotic formulation, comprising:

a mixture of beneficial probiotic microflora, comprising

lactobacillus gasseri, lactobacillus fermentum, and lactobacillus rhamnosus;

and

a pharmaceutically acceptable carrier.

2. The probiotic formulation of claim 1, wherein the mixture of beneficial probiotic microflora comprises from about 10 to 50 weight percent lactobacillus gasseri, from about 10 to 50 weight percent lactobacillus fermentum, and from about 10 to 50 weight percent lactobacillus rhamnosus.

3. The probiotic formulation of claim 1, wherein the mixture of beneficial probiotic microflora comprises from about 30 to 35 weight percent lactobacillus gasseri, from about 30 to 35 weight percent lactobacillus fermentum, and from about 30 to 35 weight percent lactobacillus rhamnosus.

4. The probiotic formulation of claim 1, wherein the mixture of beneficial probiotic microflora is about between 5 billion and 50 billion colony forming units (CFU).

5. The probiotic formulation of claim 1, wherein the mixture of beneficial probiotic microflora is 37.5 billion CFU.

6. The probiotic formulation of claim 1, wherein the pharmaceutically acceptable carrier is a capsule.

7. The probiotic formulation of claim 1, wherein the pharmaceutically acceptable carrier is a tablet.

8. The probiotic formulation of claim 1, wherein the pharmaceutically acceptable carrier is a food product.

9. The probiotic formulation of claim 1, further comprising

one or more prebiotics acting as a food source for the mixture of probiotics.

10. The probiotic formulation of claim 9, wherein the prebiotics includes inulin.

11. The probiotic formulation of claim 9, wherein the prebiotics includes oligofructose.

12. The probiotics formulation of claim 9, wherein the prebiotics includes a non-digestible oligosaccharide.

13. A method of colonizing gastrointestinal microflora in overweight individuals comprising administering a therapeutically effective amount of the mixture of beneficial probiotic microflora and the pharmaceutically acceptable carrier.

14. The method of claim 13, wherein the therapeutically effective amount is from about 10 billion to 50 billions colony forming units (CFU) of the mixture of beneficial probiotic microflora.

15. The method of claim 13, wherein the therapeutically effective amount is 37.5 billion CFU of the mixture of beneficial probiotic microflora.